CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Continuous support in the form of investments and grants from the government and
private sectors
4.1.2. Rising number of research activities involving humanised models
4.1.3. Increasing demand for personalised medicine
4.1.4. Growing number of R&D activities in pharmaceutical and biotechnology companies
4.2. Market Restraints & Challenges
4.2.1. Regulations & laws formulated for the ethical use of animals
4.2.2. Alternative methods of animal testing
4.3. Market Opportunities
4.3.1. Rising demand for humanised rat models
4.3.2. Increased production of monoclonal antibodies
CHAPTER 5. GLOBAL HUMANIZED MOUSE AND RAT MODELS MARKET – BY
TYPE
5.1. Introduction
5.2. Humanized mouse models
5.2.1. Genetic humanised mouse models
5.2.2. Cell-based humanised mouse models
5.2.2.1. Cd34 humanised mouse models
5.2.2.2. PBMC humanised mouse models
5.2.2.3. BLT humanised mouse models
5.3. Humanized rat models
CHAPTER 6. GLOBAL HUMANIZED MOUSE AND RAT MODELS MARKET –
CLINICAL TRAILS & RESEARCH
6.1. Introduction
6.2. Clinical trials
6.3. Research studies
CHAPTER 7. GLOBAL HUMANIZED MOUSE AND RAT MODELS MARKET – BY
APPLICATION
7.1. Introduction
7.2. Oncology
7.2.1 Key developments by industry players to strengthen cancer research
7.2.2 Continuous grants/funds to support cancer research studies
7.3. Neuroscience
7.3.1 Grants/funds for neurological research
7.4. Immunology and Infectious Diseases
7.4.1 Grants/funds for immunology and infectious diseases research
7.5. Toxicology
7.6. Hematopoiesis
7.7. Other Applications
CHAPTER 8. GLOBAL HUMANIZED MOUSE AND RAT MODELS MARKET - BY
END USER
8.1. Introduction
8.2. Contract research organisations
8.3. Pharmaceutical & biotechnology companies
8.4. Academic & research institutions
CHAPTER 9. GLOBAL HUMANIZED MOUSE AND RAT MODELS MARKET - BY
GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL HUMANIZED MOUSE AND RAT MODELS MARKET -
COMPANY PROFILES
10.1. Transviragen, Inc.
10.2. Horizon Discovery Group PLC
10.3. Transposagen Biopharmaceuticals, Inc.
10.4. Genoway S.A.
10.5. Hera Biolabs.
10.6. Cognosante, LLC
10.7. Charles River Laboratories
10.8. Deloitte Touche Tohmatsu Limited
10.9. Ingenious Targeting Laboratory.,
10.10. Taconic Biosciences
10.11. The Jackson Laboratory.
10.12. TransGenic Inc.
10.13. Vitalstar Biotechnology.
10.14. Axenis.
10.15. Champions Oncology, Inc.
CHAPTER 11. GLOBAL HUMANIZED MOUSE AND RAT MODELS MARKET -
COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
